{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T06:26:04Z","timestamp":1791699964056,"version":"4.3.4"},"reference-count":84,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Heart Failure with Preserved Ejection Fraction (HFpEF) is one of the most frequent causes of heart failure in the world\u2019s population (about 19\u201355%), and is commonly associated with a high rate of hospitalization (almost 70\u201380%) and with increased mortality (40\u201350% in a 5-year timeframe). The elderly are more often affected, with higher rates of hospitalizations than young people, and currently almost 70% of the population aged 65 years old has HFpEF. An increase in cardiomyocyte stiffness, thus resulting in diastolic dysfunction, increased filling pressures and heart failure with preserved ejection fraction are characteristics features of the disease. In addition, among the various causes of HFpEF, cardiac amyloidosis (CA) can provoke diastolic dysfunction and increased wall stiffness directly from intercellular deposition of insoluble proteic substances and their toxic activity. Totally, almost 30 different proteins are able to form deposits, but the most frequently involved are transthyretin and misfolded monoclonal immunoglobulin light chains, which bring to two clinical conditions called transthyretin amyloidosis (ATTR) and light-chain amyloidosis (AL). Although there has been increasing attention on ATTR-CA in recent years, the actual prevalence remains underestimated, especially in people of advanced age, as well as its real impact as a cause of HFpEF, and only data derived from autoptic exams are currently available. Moreover, CA itself often mimics HFpEF, and some conflicting data on the use of predictive scores are described in the literature. The close relationship between HFpEF and CA, especially in older population and the main pathophysiological mechanisms which bond these two conditions are described in this focused review. The need to screen red flags for ATTR-CA in elderly patients with HFpEF is urgently advised, because a prompt recognition of the disease can optimize the approach to the disease with an early therapeutic, life-saving choice.<\/jats:p>","DOI":"10.3390\/ijms252111519","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T04:15:02Z","timestamp":1730088902000},"page":"11519","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Heart Failure with Preserved Ejection Fraction and Cardiac Amyloidosis in the Aging Heart"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0899-9870","authenticated-orcid":false,"given":"Marco","family":"Tana","sequence":"first","affiliation":[{"name":"Internal Medicine and Cardiovascular Ultrasound Unit, Medical Department, SS. Annunziata Hospital, 66100 Chieti, Italy"},{"name":"School of Internal Medicine, Faculty of Medicine, G. D\u2019Annunzio University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Piccinini","sequence":"additional","affiliation":[{"name":"School of Internal Medicine, Faculty of Medicine, G. D\u2019Annunzio University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Moffa","sequence":"additional","affiliation":[{"name":"School of Internal Medicine, Faculty of Medicine, G. D\u2019Annunzio University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-7866","authenticated-orcid":false,"given":"Claudio","family":"Tana","sequence":"additional","affiliation":[{"name":"Geriatric Clinic, SS. Annunziata Hospital, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Beghini, A., Sammartino, A.M., Papp, Z., von Haehling, S., Biegus, J., Ponikowski, P., Adamo, M., Falco, L., Lombardi, C.M., and Pagnesi, M. (2024). 2024 update in heart failure. ESC Heart Fail., ahead of print.","DOI":"10.1002\/ehf2.14857"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Teramoto, K., Teng, T.H.K., Chandramouli, C., Tromp, J., Sakata, Y., and Lam, C.S.P. (2022). Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction. Card. Fail. Rev., 8.","DOI":"10.15420\/cfr.2022.06"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Abdin, A., B\u00f6hm, M., Shahim, B., Karlstr\u00f6m, P., Kulenthiran, S., Skouri, H., and Lund, L.H. (2024). Heart failure with preserved ejection fraction epidemiology, pathophysiology, diagnosis and treatment strategies. Int. J. Cardiol., 412.","DOI":"10.1016\/j.ijcard.2024.132304"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart Failure With Preserved Ejection Fraction in Perspective","volume":"124","author":"Pfeffer","year":"2019","journal-title":"Circ. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"Skibelund AKESCScientific Document Group 2023 Focused Update of the 2021 ESCGuidelines for the diagnosis treatment of acute chronic heart failure: Developed by the task force for the diagnosis treatment of acute chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"McDonagh","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2014.08.036","article-title":"Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction","volume":"64","author":"Mentz","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tana, M., Tana, C., Guglielmi, M.D., Stefanelli, A., Mantini, C., and Porreca, E. (2024). Current Perspectives on Atrial Amyloidosis: A Narrative Review. Rev. Cardiovasc. Med., 25.","DOI":"10.31083\/j.rcm2502073"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Tana, M., Tana, C., Rossi, D., Mantini, C., Gallina, S., Ricci, F., and Porreca, E. (2024). Thromboembolic and bleeding risk in cardiac amyloidosis. J. Thromb. Haemost., ahead of print.","DOI":"10.1016\/j.jtha.2024.05.018"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Tana, M., Tana, C., Panarese, A., Mantini, C., Ricci, F., and Porreca, E. (2023). Clinical and Cardiovascular Magnetic Resonance Imaging Features of Cardiac Amyloidosis. Rev. Cardiovasc. Med., 24.","DOI":"10.31083\/j.rcm2410291"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"s30","DOI":"10.7861\/clinmedicine.18-2-s30","article-title":"Cardiac amyloidosis","volume":"18","author":"Hawkins","year":"2018","journal-title":"Clin. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-med-052918-020140","article-title":"Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable","volume":"71","author":"Rubin","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Rapezzi","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.23736\/S0031-0808.22.04649-3","article-title":"Cardiac amyloidosis: A significant blind spot of the H2FPEF score","volume":"65","author":"Duca","year":"2023","journal-title":"Panminerva Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jacc.2019.06.053","article-title":"Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week","volume":"74","author":"Triposkiadis","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Michels da Silva, D., Langer, H., and Graf, T. (2019). Inflammatory and Molecular Pathways in Heart Failure-Ischemia, HFpEF and Transthyretin Cardiac Amyloidosis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092322"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1152\/japplphysiol.00374.2015","article-title":"Myocardial hypertrophy and its role in heart failure with preserved ejection fraction","volume":"119","author":"Heinzel","year":"2015","journal-title":"J. Appl. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wang, N.P., Erskine, J., Zhang, W.W., Zheng, R.H., Zhang, L.H., Duron, G., Gendreau, J., and Zhao, Z.Q. (2017). Recruitment of macrophages from the spleen contributes to myocardial fibrosis and hypertension induced by angiotensin II. J. Renin Angiotensin Aldosterone Syst., 18.","DOI":"10.1177\/1470320317706653"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1253\/circj.CJ-12-0664","article-title":"Cyclic GMP-dependent signaling in cardiac myocytes","volume":"76","author":"Takimoto","year":"2012","journal-title":"Circ. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure with Preserved Ejection Fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s12471-016-0814-x","article-title":"Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction?","volume":"24","author":"Alogna","year":"2016","journal-title":"Neth. Heart J."},{"key":"ref_21","first-page":"17.1.1","article-title":"Formation and functions of protein sulfenic acids","volume":"18","author":"Poole","year":"2004","journal-title":"Curr. Protoc. Toxicol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1021\/pr901099e","article-title":"Identification of cysteine, methionine and tryptophan residues of actin oxidized in vivo during oxidative stress","volume":"9","author":"Fedorova","year":"2010","journal-title":"J. Proteome Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.hfc.2024.02.002","article-title":"Pathophysiology of Cardiac Amyloidosis","volume":"20","author":"Morfino","year":"2024","journal-title":"Heart Fail. Clin."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1021\/bi301313b","article-title":"Age-related oxidative modifications of transthyretin modulate its amyloidogenicity","volume":"52","author":"Zhao","year":"2013","journal-title":"Biochemistry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00726-003-0011-2","article-title":"Free radical-mediated oxidation of free amino acids and amino acid residues in proteins","volume":"25","author":"Stadtman","year":"2003","journal-title":"Amino Acids"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijcard.2009.04.044","article-title":"Systemic and microvascular oxidative stress induced by light chain amyloidosis","volume":"145","author":"Migrino","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","article-title":"Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway","volume":"107","author":"Shi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1074\/jbc.M205616200","article-title":"Endothelin-1-specific activation of B-type natriuretic peptide gene via p38 mitogen-activated protein kinase and nuclear ETS factors","volume":"278","author":"Pikkarainen","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ajh.27177","article-title":"Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment","volume":"99","author":"Gertz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijcard.2016.06.040","article-title":"RICA investigators group. Precipitating factors of heart failure admission: Differences related to age and left ventricular ejection fraction","volume":"219","author":"Formiga","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s00392-019-01477-z","article-title":"Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction","volume":"108","author":"Chen","year":"2019","journal-title":"Clin. Res. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"642","DOI":"10.7326\/0003-4819-139-8-200310210-00007","article-title":"Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: The Framingham Heart Study","volume":"139","author":"Vasan","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Stoicescu, L., Cri\u015fan, D., Morgovan, C., Avram, L., and Ghibu, S. (2024). Heart Failure with Preserved Ejection Fraction: The Pathophysiological Mechanisms behind the Clinical Phenotypes and the Therapeutic Approach. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25020794"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.62347\/ZOMD7815","article-title":"Prognostic value of serum IGF-1, Gal-3, and PTX-3 levels in elderly patients with chronic heart failure","volume":"16","author":"Zhang","year":"2024","journal-title":"Am. J. Transl. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/ncpcardio1245","article-title":"Diastolic heart failure: Mechanisms and controversies","volume":"5","author":"Ouzounian","year":"2008","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/01.RES.0000129254.25507.d6","article-title":"What mechanisms underlie diastolic dysfunction in heart failure?","volume":"94","author":"Kass","year":"2004","journal-title":"Circ. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/FJC.0000000000000423","article-title":"Antioxidant Treatment Improves Cardiac Dysfunction in a Murine Model of Premature Aging","volume":"68","author":"Hemmeryckx","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sanada, F., Taniyama, Y., Muratsu, J., Otsu, R., Shimizu, H., Rakugi, H., and Morishita, R. (2018). Source of Chronic Inflammation in Aging. Front. Cardiovasc. Med., 5.","DOI":"10.3389\/fcvm.2018.00012"},{"key":"ref_42","first-page":"775","article-title":"Age and the Cardiovascular System","volume":"327","author":"Tomomatsu","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/01.ATV.0000160548.78317.29","article-title":"Mechanisms, pathophysiology, and therapy of arterial stiffness","volume":"25","author":"Zieman","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1001\/jama.297.10.1058-b","article-title":"Classifying systolic and diastolic heart failure","volume":"297","author":"Florea","year":"2007","journal-title":"JAMA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1161\/01.RES.0000269183.13937.e8","article-title":"Direct evidence of endothelial oxidative stress with aging in humans: Relation to impaired endothelium-dependent dilation and upregulation of nuclear factor-kappaB","volume":"100","author":"Donato","year":"2007","journal-title":"Circ Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.freeradbiomed.2013.07.003","article-title":"Oxidative stress and vascular inflammation in aging","volume":"65","author":"Angulo","year":"2013","journal-title":"Free Radic Biol. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1161\/01.CIR.0000048123.22359.A0","article-title":"Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: Implications for systolic and diastolic reserve limitations","volume":"107","author":"Kawaguchi","year":"2003","journal-title":"Circulation"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Chiao, Y.A., and Rabinovitch, P.S. (2015). The Aging Heart. Cold Spring Harb. Perspect. Med., 5.","DOI":"10.1101\/cshperspect.a025148"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cardiores.2006.10.002","article-title":"The role of TGF-beta signaling in myocardial infarction and cardiac remodeling","volume":"74","author":"Bujak","year":"2007","journal-title":"Cardiovasc. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.yjmcc.2010.01.006","article-title":"Involvement of NADPH oxidase in age-associated cardiac remodeling","volume":"48","author":"Wang","year":"2010","journal-title":"J. Mol. Cell Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/clc.4960110802","article-title":"The old-age heart: Normal aging changes which can produce or mimic cardiac disease","volume":"11","author":"Waller","year":"1988","journal-title":"Clin. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/13506129.2021.1882979","article-title":"Clinicopathological features of clinically undiagnosed sporadic transthyretin cardiac amyloidosis: A forensic autopsy-based series","volume":"28","author":"Ichimata","year":"2021","journal-title":"Amyloid"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Hyer, C., Campbell, C., and Kahwash, R. (2021). Clinical implications of atrial natriuretic peptide amyloidosis. BMJ Case Rep., 14.","DOI":"10.1136\/bcr-2021-242856"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Yang, Z., Subati, T., Kim, K., Murphy, M.B., Dougherty, O.P., Christopher, I.L., Van Amburg, J.C., Woodall, K.K., Barnett, J.V., and Murray, K.T. (2022). Natriuretic Peptide Oligomers Cause Proarrhythmic Metabolic and Electrophysiological Effects in Atrial Myocytes. Circ. Arrhythm. Electrophysiol., 15.","DOI":"10.1161\/CIRCEP.121.010636"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1161\/01.CIR.0000034511.06350.DF","article-title":"Atrial amyloidosis: An arrhythmogenic substrate for persistent atrial fibrillation","volume":"106","author":"Peters","year":"2002","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1172\/JCI62876","article-title":"MicroRNAs in cardiovascular disease: From pathogenesis to prevention and treatment","volume":"123","author":"Quiat","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0009-8981(03)00003-2","article-title":"Protein carbonyl groups as biomarkers of oxidative stress","volume":"329","author":"Rossi","year":"2003","journal-title":"Clin. Chim. Acta"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Dai, Y., Guo, Y., Tang, W., Chen, D., Xue, L., Chen, Y., Guo, Y., Wei, S., Wu, M., and Dai, J. (2024). Reactive oxygen species-scavenging nanomaterials for the prevention and treatment of age-related diseases. J. Nanobiotechnol., 22.","DOI":"10.1186\/s12951-024-02501-9"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Silvestro, S., Raffaele, I., and Mazzon, E. (2023). Modulating Stress Proteins in Response to Therapeutic Interventions for Parkinson\u2019s Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216233"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Liu, G., Yang, C., Wang, X., Chen, X., Wang, Y., and Le, W. (2023). Oxygen metabolism abnormality and Alzheimer\u2019s disease: An update. Redox Biol., 68.","DOI":"10.1016\/j.redox.2023.102955"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1089\/ars.2016.6802","article-title":"The Proteasome and Oxidative Stress in Alzheimer\u2019s Disease","volume":"25","author":"Pomatto","year":"2016","journal-title":"Antioxid. Redox Signal."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1006\/bbrc.1996.5997","article-title":"Oxidative stress is found in amyloid deposits in systemic amyloidosis","volume":"232","author":"Ando","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Fiore, M., Cambieri, C., Libonati, L., Moret, F., D\u2019Andrea, E., Di Certo, M.G., Passananti, C., Gabanella, F., Corbi, N., and Garibaldi, M. (2024). Oxidative Stress in Transthyretin-Mediated Amyloidosis: An Exploratory Study. Antioxidants, 13.","DOI":"10.3390\/antiox13080998"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ejhf.2726","article-title":"Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: A pooled analysis of three randomized trials","volume":"25","author":"Ferreira","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: An individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","article-title":"Sacubitril\/Valsartan in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Pre-Specified Participant-Level Pooled Analysis of PARAGLIDE-HF and PARAGON-HF","volume":"44","author":"Vaduganathan","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_68","first-page":"130","article-title":"L\u2019\u00e9tude clinique du mois. PARAGON-HF: Sacubitril\/valsartan (Entresto\u00ae) dans l\u2019insuffisance cardiaque \u00e0 fraction d\u2019\u00e9jection pr\u00e9serv\u00e9e (HFpEF) [The PARAGON-HF trial]","volume":"75","author":"Tridetti","year":"2020","journal-title":"Rev. Med. Liege."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Peikert, A., Martinez, F.A., Vaduganathan, M., Claggett, B.L., Kulac, I.J., Desai, A.S., Jhund, P.S., De Boer, R.A., Demets, D., and Hernandez, A.F. (2022). Efficacy and Safety of Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. Circ. Heart Fail., 15.","DOI":"10.1161\/CIRCHEARTFAILURE.122.010080"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","article-title":"Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation","volume":"117","author":"Kolijn","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s10741-022-10220-2","article-title":"Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: What is the evidence?","volume":"27","author":"Wichaiyo","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/CIRCRESAHA.108.175141","article-title":"Activation of Na+\/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure","volume":"103","author":"Nakamura","year":"2008","journal-title":"Circ. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1515\/jbcpp-2023-0029","article-title":"Protecting cardiomyocytes from hypoxia-reoxygenation injury, empaglifozin and liraglutide alone or in combination?","volume":"35","author":"Amici","year":"2024","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Chen, B., Guo, J., Ye, H., Wang, X., and Feng, Y. (2024). Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review). Mol. Med. Rep., 29.","DOI":"10.3892\/mmr.2024.13197"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_77","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Fontana, M., Berk, J.L., Gillmore, J.D., Witteles, R.M., Grogan, M., Drachman, B., Damy, T., Garcia-Pavia, P., Taubel, J., and Solomon, S.D. (2024). HELIOS-B Trial Investigators. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N. Engl. J. Med., ahead of print.","DOI":"10.1056\/NEJMoa2409134"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 Inhibitor Therapy in Patients with Transthyretin Amyloid Cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1002\/ehf2.13876","article-title":"Transcatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: A systematic review and meta-analysis","volume":"9","author":"Cannata","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00392-017-1170-6","article-title":"Heart failure with preserved ejection fraction: Current management and future strategies: Expert opinion on the behalf of the Nucleus of the \u201cHeart Failure Working Group\u201d of the German Society of Cardiology (DKG)","volume":"107","author":"Birner","year":"2018","journal-title":"Clin. Res. Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Delrue, C., Vandendriessche, A., Dendooven, A., Van der Linden, M., Speeckaert, M.M., and De Bruyne, S. (2024). Pilot Study on the Use of Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy for Diagnosing and Characterizing Cardiac Amyloidosis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179358"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Fotiou, D., Theodorakakou, F., and Kastritis, E. (2021). Biomarkers in AL Amyloidosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222010916"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/21\/11519\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:21:18Z","timestamp":1760113278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/21\/11519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":84,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["ijms252111519"],"URL":"https:\/\/doi.org\/10.3390\/ijms252111519","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]}}}